Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
+0.03 (0.62%)
Real-time:   12:45PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.81 - 4.99
52 week 4.01 - 8.38
Open 4.82
Vol / Avg. 653,486.00/1.37M
Mkt cap 586.62M
P/E     -
Div/yield     -
EPS -1.44
Shares 119.22M
Beta 2.71
Inst. own 67%
May 2, 2018
Q1 2018 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 12, 2018
Keryx Biopharmaceuticals Inc at Cowen Health care Conference - 1:30PM EDT - Add to calendar
Feb 7, 2018
Q4 2017 Keryx Biopharmaceuticals Inc Earnings Release
Feb 7, 2018
Q4 2017 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Jan 10, 2018
Keryx Biopharmaceuticals Inc at JPMorgan Healthcare Conference Breakout Session
Jan 10, 2018
Keryx Biopharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Nov 28, 2017
Keryx Biopharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -162.88% -269.52%
Operating margin -166.00% -167.69%
EBITD margin - -167.69%
Return on average assets - -
Return on average equity - -
Employees 193 -
CDP Score - -


1 Marina Park Dr
BOSTON, MA 02210-1832
United States - Map
+1-617-4663500 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Officers and directors

Michael W. Rogers Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Gregory Paul Madison Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Scott A. Holmes Chief Financial Officer, Treasurer
Age: 42
Bio & Compensation  - Reuters
Christine A. Carberry Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Douglas M. Jermasek Vice President of Marketing and Strategy
Bio & Compensation  - Reuters
Brian R. Adams General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Lora Pike Senior Director
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 48
Bio & Compensation  - Reuters
Mark J. Enyedy Independent Director
Age: 53
Bio & Compensation  - Reuters